Prostate_Cancer_Genomic_Classifier_Sources_Sought.pdf

PDF 97 KB Posted

Attached to
Q301--Prostate Reference Lab Testing Services
Solicitation number
36C25027Q0113
Issued by

About this file

This is a Sources Sought Notice issued by the Department of Veterans Affairs, Veterans Health Administration, through Network Contracting Office (NCO) 10 in Columbus, Ohio for market research purposes under FAR Part 10. The notice is not a solicitation and does not constitute a commitment to award a contract; responses are voluntary and non-binding.

The VA seeks qualified vendors to provide prostate cancer genomic classifier testing services to support clinical decision-making for Veterans with prostate cancer. The required services must analyze tissue specimens from prostate biopsy and prostatectomy procedures and deliver clinically actionable genomic information to assess disease aggressiveness, disease progression risk, metastasis risk, and prostate cancer-specific mortality. Clinical reports must support multiple treatment pathways including active surveillance, definitive treatment planning, radiation therapy decisions, post-prostatectomy management, risk stratification, and treatment intensification. The NAICS code is 621511 (Medical Laboratories) and the Product Service Code is Q301 (Medical Laboratory Testing).

Minimum capabilities required include receipt and accessioning of prostate tissue specimens at VA facilities, genomic analysis using a validated molecular testing platform, patient-specific risk reports, clinical reporting supporting treatment decisions, electronic ordering and reporting capabilities, CLIA certification and CAP accreditation or equivalent, specimen shipping and logistics support, technical and clinical customer support, defined turnaround times, nationwide service capability for Veterans Health Administration facilities, and clinically validated predictive information regarding long-term metastasis and prostate cancer-specific mortality risk with identified maximum validated prediction horizons. Interested vendors must submit a capability statement not exceeding five pages to maryjane.crim@va.gov by the date specified in the public posting, addressing company information, business size designation, socioeconomic status, laboratory certifications, geographic service coverage, turnaround times, clinical validation evidence, and detailed responses to 13 specific questions regarding testing methodology, specimen types, predictive outcomes, and peer-reviewed publications supporting clinical performance claims.

View the file

Other files

File Type Posted
36C25027Q0113.docx DOCX document

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

SOURCES SOUGHT NOTICE

Prostate Cancer Genomic Classifier Testing Services

THIS IS NOT A SOLICITATION

This is a Sources Sought Notice only. It is issued solely for information and planning purposes and does not constitute a solicitation. This notice is issued in accordance with Federal Acquisition Regulation (FAR) Part 10, Market Research.

The Department of Veterans Affairs (VA) is conducting market research to identify qualified sources capable of providing prostate cancer genomic classifier testing services. The purpose of this notice is to determine the availability of capable businesses and inform an appropriate acquisition strategy.

This notice shall not be construed as a commitment by the Government to issue a solicitation or award a contract. Responses are not offers and cannot be accepted by the Government to form a binding contract.

The Government will not reimburse any costs associated with responding to this notice.

Agency Information

Agency Department of Veterans Affairs, Veterans Health Administration

Contracting Office Network Contracting Office (NCO) 10, Ohio, Columbus VAAC

NAICS Code 621511 - Medical Laboratories

Product Service Code Q301 - Medical Laboratory Testing

Requirement Description The Department of Veterans Affairs requires genomic testing services to support clinical decision-making for Veterans diagnosed with prostate cancer.

The required services shall analyze tissue specimens obtained from prostate biopsy and/or prostatectomy procedures and provide clinically actionable genomic information to assist treating physicians in assessing disease aggressiveness, risk of disease progression, risk of metastasis, and prostate cancer-specific mortality.

The resulting clinical report shall provide information that may assist healthcare providers in evaluating treatment options, including:

• Active surveillance

• Definitive treatment planning

• Radiation therapy decision-making

• Post-prostatectomy management

• Risk stratification

• Treatment intensification considerations

The Government is seeking information from vendors capable of providing commercially available genomic classifier testing services that support personalized treatment decision-making for patients diagnosed with localized, recurrent, or advanced prostate cancer.

Minimum Capabilities

1. Receipt and accessioning of prostate tissue specimens collected at VA medical facilities.

2. Genomic analysis utilizing a validated molecular testing platform.

3. Generation of patient-specific reports that assess risk of disease progression and/or metastasis.

4. Clinical reporting that supports treatment decision-making for prostate cancer patients.

5. Electronic ordering and reporting capabilities.

6. Medical laboratory services performed within laboratories maintaining all required applicable certifications and accreditations, including CLIA certification and CAP accreditation or equivalent.

7. Specimen shipping instructions and logistics support.

8. Technical and clinical customer support.

9. Turnaround times from specimen receipt through final report issuance.

10. Nationwide service capability sufficient to support Veterans Health Administration facilities.

11. Ability to provide clinically validated predictive information regarding long-term risk of prostate cancer metastasis and prostate cancer-specific mortality, including identification of the maximum validated prediction horizon supported by published clinical evidence.

Vendor Response Information Interested parties are requested to provide the following information:

• Company name and physical address

• Unique Entity Identifier (UEI)

• Business size designation and socioeconomic status

• Point of contact name, title, telephone number, and email address

• Available contract vehicles

• Description of prostate cancer genomic testing services offered

• Laboratory certifications and accreditations

• Geographic service coverage and specimen logistics process

• Typical report turnaround times

• Published evidence supporting clinical validation and clinical utility of the testing methodology

• Clinical validation studies supporting metastasis prediction and prostate cancer-specific mortality prediction, including the duration of validated follow-up periods

Specific Questions

1. Does your organization currently offer a genomic classifier or molecular assay intended to support treatment decision-making for prostate cancer patients?

2. What specimen types are accepted for testing?

3. Describe the genomic or molecular methodology utilized.

4. What clinical outcomes or risk assessments are included in the final report?

5. Is testing performed within your organization's laboratory facilities or through subcontracted laboratories?

6. Describe the laboratory certifications and accreditations maintained for the testing services.

7. Describe electronic ordering, specimen tracking, and reporting capabilities.

8. What is the average turnaround time from specimen receipt to report delivery?

9. Has your organization previously provided similar services to Federal agencies or integrated healthcare systems?

10. Are there any unique features, capabilities, or differentiators associated with your prostate cancer genomic testing service?

11. Describe the longest clinically validated period for which your test has demonstrated the ability to predict the risk of metastatic disease progression. Include supporting peer-reviewed publications and study follow-up durations.

12. Describe the longest clinically validated period for which your test has demonstrated the ability to predict prostate cancer-specific mortality. Include supporting peer-reviewed publications and study follow-up durations.

13. For each predictive outcome reported by your test, identify the outcome measured (for example, metastasis, biochemical recurrence, prostate cancer-specific mortality, or overall survival); length of validated follow-up; study population size; whether validation was prospective, retrospective, or both;

and the relevant peer-reviewed publications supporting the claimed predictive performance.

Submission Instructions Interested parties shall submit a capability statement not to exceed five (5) pages. Responses should be sufficiently detailed to permit the Government to assess the respondent's capabilities and the extent to which the proposed testing service satisfies the requirements described in this notice.

Responses shall be submitted electronically by the date and time identified in the public posting to the Contracting Officer at maryjane.crim@va.gov.

Disclaimer This Sources Sought Notice is for market research purposes only. Information obtained through this notice may be used by the Government in developing its acquisition strategy. Submission of a response is voluntary and will not affect a firm's ability to participate in any future solicitation. The Government may contact respondents for clarification or additional information but is under no obligation to do so.

File details come from the government source that posted it. Updated .